Allspring Global Investments Holdings LLC Cuts Stock Position in Natera, Inc. $NTRA

Key Points

• Allspring Global Investments Holdings LLC reduced its stake in Natera, Inc. by 32.0%, now holding 522,525 shares worth approximately $83.98 million after selling 245,987 shares.
• Institutional investors dominate Natera's ownership, holding 99.90% of the company's stock, with notable increases in holdings from firms like Price T Rowe Associates and UBS Asset Management.
• Natera reported a quarterly revenue increase of 32.2% year-over-year, despite missing earnings expectations, with a current consensus target price of $192.88 from analysts.

Allspring Global Investments Holdings LLC trimmed its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 32.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 522,525 shares of the medical research company's stock after selling 245,987 shares during the period. Allspring Global Investments Holdings LLC owned 0.38% of Natera worth $83,980,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in shares of Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares during the last quarter. Nuveen LLC purchased a new stake in Natera during the 1st quarter worth approximately $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Natera by 140.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock valued at $177,298,000 after acquiring an additional 732,156 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Natera by 9.9% in the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after acquiring an additional 660,538 shares in the last quarter. Finally, Ninety One UK Ltd boosted its stake in shares of Natera by 149.1% in the second quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company's stock worth $95,111,000 after acquiring an additional 336,985 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Activity

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total value of $479,970.00. Following the sale, the insider owned 117,559 shares in the company, valued at $18,808,264.41. The trade was a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John Fesko sold 678 shares of the company's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the completion of the transaction, the insider directly owned 152,747 shares in the company, valued at approximately $23,746,048.62. This trade represents a 0.44% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,464 shares of company stock worth $10,963,125. 5.63% of the stock is owned by company insiders.

Natera Trading Up 2.9%

Shares of NTRA stock opened at $174.17 on Tuesday. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $183.00. The company's 50-day moving average price is $165.33 and its 200-day moving average price is $157.54. The stock has a market cap of $23.90 billion, a price-to-earnings ratio of -91.19 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period last year, the firm earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on NTRA. Barclays reissued an "overweight" rating and issued a $210.00 price objective (up from $190.00) on shares of Natera in a research note on Friday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Natera in a report on Wednesday, October 8th. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 target price for the company in a research report on Monday, July 28th. Cowen restated a "buy" rating on shares of Natera in a research report on Friday, August 8th. Finally, Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $192.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.